MyMeds&Me today announced that Aurinia Pharmaceuticals Inc. has selected the Reportum QuickStart platform to streamline the capture, processing, and management of safety data for the investigational drug voclosporin following recent positive Phase III results.
Aurinia will implement the Reportum QuickStart platform to support the launch of voclosporin, enabling adverse event, product quality complaint, and medical information requests to be captured by field-based representatives, medical science liaisons, and speciality pharmacy providers, as well as direct from healthcare professionals and consumers.
Offering the full safety data-capture functionality of the Reportum platform, QuickStart is a preconfigured and validated solution to facilitate rapid set-up and cost-effective deployment. QuickStart enables pharmacovigilance teams of all sizes to benefit from a robust and scalable drug safety system that can be implemented within a matter of weeks.
